Amyotrophic lateral sclerosis (ALS) and Huntington’s disease are two rare diseases in which nerve cells die and the person gets steadily worse. Cannabis medicines have been tested in people with both. In ALS, a randomised trial of the THC:CBD mouth spray nabiximols found a small improvement in muscle stiffness. In Huntington’s disease, a randomised trial of the same spray found no benefit. A widely shared story about one woman with ALS is also often used as proof, but it cannot prove anything. Reading these three side by side shows you how to judge any cannabis claim: what was measured, in how many people and for how long.
Read this first. This is not medical advice. Cannabis does not treat ALS or Huntington’s disease. Do not use it in place of care from a neurologist (a doctor who specialises in the brain and nerves). Do not use it in place of drugs that slow the disease, where these exist. For ALS there is riluzole (a tablet that slows the disease modestly) and some other drugs. For Huntington’s disease, no drug that slows the disease is approved. In Thailand, cannabis flower is a controlled herb. It may be sold only against a prescription on form PT 33.
1. Amyotrophic lateral sclerosis (ALS)
ALS is also called motor neurone disease, or Lou Gehrig’s disease. In ALS the motor neurons die. These are the nerve cells in the brain and spinal cord that tell the muscles to move.
As these cells die, the person slowly loses control of the arms and legs, then of breathing, swallowing and speech. The muscles weaken and waste away. ALS is fatal. At best, the available drugs slow it only modestly.
What people usually claim
The common claim has three parts. First, cannabis may help people with ALS by reducing pain, drooling, loss of appetite and spasticity (stiff, tight muscles that resist movement). Second, THC combined with other cannabinoids helped laboratory mice with an ALS-like disease. Third, trials in humans are needed.
Nearly all of this is about symptoms, not about the disease itself. The mouse result is the only exception. After an animal result, the correct next step is to call for human trials. So up to this point, the claim does not go beyond the evidence.
What happened next: the CANALS trial
A research team led by Riva published the CANALS trial in The Lancet Neurology in 2019. It tested nabiximols (brand name Sativex). Nabiximols is a spray of roughly equal parts THC and CBD. It is sprayed inside the mouth and absorbed through the lining of the mouth (an “oromucosal” spray). Doctors also use it for spasticity in multiple sclerosis.
The trial design gives the result its weight:
- Multicentre: patients came from several hospitals, not just one.
- Randomised: chance, not the doctor, decided who got the real spray.
- Placebo-controlled: the comparison group got a dummy spray with no cannabinoids.
- Double-blind: neither the patients nor the doctors knew who had which spray. This stops expectations from colouring the scores.
- Phase 2: a mid-sized trial that checks safety and looks for early signs of benefit. Larger confirming trials come later.
Sixty people with motor neurone disease were randomised, and 59 were analysed. Treatment lasted six weeks. The main outcome, chosen before the trial began, was spasticity. It was measured on the Modified Ashworth Scale. With this bedside test, the examiner moves the patient’s limb and grades how much the muscle resists. A higher score means stiffer muscles.
Result: spasticity scores in the nabiximols group improved slightly, by an average of −0.11. Scores in the placebo group got worse, by +0.16. The spray was well tolerated, and there were no serious adverse events (serious harmful side effects). The authors recommended testing it in larger trials.
This is a genuinely positive result in a group of patients where trials are hard to run. It should be reported as positive. But be exact about what it covers: a six-week phase 2 trial that measured spasticity. It tells you nothing about survival, how fast the disease progresses, or the loss of motor neurons. It is symptom control. In ALS, symptom control matters a great deal for daily life.
What you can do: if stiffness is a problem, ask the neurologist to record a Modified Ashworth score before any new treatment, then again after a few weeks. That way you see in numbers whether the treatment changed the stiffness, instead of relying on impressions.
2. The Cathy Jordan story, and why one survivor proves nothing
Cathy Jordan was a medical cannabis campaigner in Florida, in the United States. Her story, as it is usually told, runs like this. She was diagnosed with ALS in 1986. Most people with ALS live only two to five years after symptoms begin.
She began using cannabis in the late 1980s and credited it with keeping her alive. She died in July 2024, aged 74, about 38 years after her diagnosis.
An interview with her is widely quoted. In it, she described cannabis as protecting her nerve cells. She also pointed out that ALS patient associations campaign for the right to die with dignity. “But what about my right to life?” she asked.
As a human story, it is powerful. Her point about the right to live is serious and deserves respect.
As medical evidence, it proves nothing, for two reasons.
First, the diagnosis was never independently checked. No medical journal recorded her diagnosis or how her disease developed. The story rests on her own account and on press reports.
Second, even if the diagnosis was correct, ALS survival varies very widely. This problem is specific to ALS. Most patients die within a few years, but a small minority live for decades. Stephen Hawking, the British physicist, was diagnosed at 21 and lived another 55 years. Nobody has suggested that cannabis played any part in his survival.
Long survivors exist and are documented. Now imagine a treatment that does nothing at all. In ALS you would still, with certainty, find some long survivors who had used it. So finding one such survivor tells you nothing about the treatment. This is the general weakness of personal testimony as medical evidence, and ALS shows it more clearly than any other disease.
What you can do: when a survival story is shared in a patient group, ask two questions. Did a doctor confirm the diagnosis in a published record? Does this disease normally produce long survivors without any treatment? If either answer is unclear, take the story as encouragement, not as a reason to change treatment.
3. Huntington’s disease
Huntington’s disease is inherited: it is passed from parent to child through a faulty gene. It causes involuntary movements, a decline in memory and thinking, and psychiatric symptoms such as changes in mood and behaviour.
There is a specific reason to expect cannabinoids to matter here. People with Huntington’s disease have far fewer CB1 receptors in the striatum. CB1 receptors are docking sites on brain cells where THC attaches (see the endocannabinoid system). The striatum is a region deep in the brain that helps control movement, and it is the region the disease attacks.
The animal studies
Research groups in Spain have tested THC and CBD in animal models of Huntington’s disease. These include the group of Javier Fernández-Ruiz at Complutense University in Madrid. The best-known THC result comes from Blázquez and colleagues (2011).
They used R6/2 mice. These are laboratory mice bred to carry a piece of the faulty human huntingtin gene, the gene behind Huntington’s disease. In these mice, THC improved movement symptoms. It also reduced the brain damage seen under the microscope and the molecular changes caused by the disease.
The authors argued that losing CB1 receptors in the striatum is itself a key driver of the disease. That is a strong preclinical result (a laboratory and animal result, before any human testing). It also targets something that makes biological sense.
The human trials
All three human trials used a crossover design. Each patient received the real drug and the placebo in turn, in random order. Each patient therefore served as their own comparison. All three were also double-blind.
- CBD alone (Consroe and colleagues, University of Arizona, 1991). 15 patients took about 10 mg of CBD per kg of body weight per day for six weeks. For a 60 kg person, that is about 600 mg a day. CBD did no better than placebo on symptoms, and it was not toxic.
- Nabilone (Curtis and colleagues, 2009). Nabilone is a laboratory-made drug that acts like THC, taken as a capsule. 44 patients took part. There was no significant difference on the main outcome, the total movement score. Scores for chorea (sudden, jerky, dance-like movements) and for psychiatric symptoms did improve.
- Nabiximols (López-Sendón Moreno and colleagues, 2016). 26 patients were randomised, and treatment lasted 12 weeks. The spray was safe. It did no better than placebo on movement, thinking, behaviour or everyday functioning.
The wider picture
In 2022, Oikonomou and Jost published a systematic review of randomised controlled trials of cannabis-based medicines in movement disorders. A systematic review collects every trial on a question using a fixed, stated method. It found these three randomised trials in Huntington’s disease. Only one, the nabilone trial, found symptom relief.
The review’s overall conclusion applies here. There are only a few trials, they are small, and they were designed differently. So no reliable conclusion can be drawn from them.
What you can do: if a family member with Huntington’s disease wants to try a cannabinoid, first name the symptom you hope to change. The only partial signal so far is nabilone for chorea and psychiatric symptoms. Ask the neurologist whether that applies to your family member. This keeps you from paying for a product for symptoms where trials found nothing.
4. Two diseases, two lessons
| ALS / motor neurone disease | Huntington’s disease | |
|---|---|---|
| Biological reason to expect an effect | General: protecting nerve cells and easing muscle stiffness | Specific: loss of CB1 receptors in the striatum |
| Animal evidence | Positive | Positive: movement and brain damage improved |
| Randomised trials in humans | One positive phase 2 trial on spasticity (CANALS, nabiximols) | Three small trials: CBD negative, nabiximols negative, nabilone partly positive (chorea) |
| What is claimed | Symptom relief: pain, spasticity, drooling, appetite | Symptom relief |
| What is not claimed | Longer survival, or slowing the disease | Longer survival, or slowing the disease |
The clearest comparison is the product itself. The same THC:CBD spray eased spasticity in motor neurone disease and showed no benefit in Huntington’s disease. The trials measured different symptoms, but the drug was the same.
Huntington’s disease had the stronger biological explanation: a documented receptor loss in exactly the brain region the disease attacks. It still produced the weaker trial result. This pattern repeats across neurology. A convincing mechanism is a good reason to run a trial. It does not replace the trial.
What you can do: when you read that cannabis “should work” for a disease because of how it acts in the brain, look for a randomised human trial on the symptom you care about. If there is none, treat the claim as unproven.
5. What this means for patients and families
Both diseases keep getting worse, and both have few treatment options. Families often look beyond what doctors offer. That is understandable, and it is not irrational.
The evidence supports something narrow but real: managing symptoms, especially spasticity. CANALS gives randomised evidence for this in motor neurone disease. Spasticity is also where cannabinoids have their best-established role in general. Pain, sleep, appetite and drooling are fair topics for the same conversation with the doctor.
The evidence does not support any effect on the disease itself. Nothing in this article slows the loss of nerve cells in a person.
For both diseases, the practical steps are the same:
- Keep cannabis use inside the neurology service. The neurologist can then check it against the patient’s other medicines and spot changes early. See the drug interaction list.
- Choose one named symptom to target, for example stiffness. Only then can you tell whether the treatment worked.
- Agree on a trial period and a stopping rule with the doctor before starting. For example: “If the stiffness score has not improved after the agreed number of weeks, we stop.” This keeps you from continuing a treatment that does nothing.
- Do not let cannabis replace proven care. That means drugs that slow the disease where they exist (riluzole and others for ALS; none is approved for Huntington’s), breathing support, nutritional support and palliative care (care focused on comfort and quality of life). All of these have better evidence for the outcomes patients care about most.
6. In Thailand
Translator’s note: cannabis flower is a controlled herb under the Notification of the Ministry of Public Health Re: Controlled Herbs (Cannabis), B.E. 2568. The notification was issued under the Thai Traditional Medicine Protection Act B.E. 2542 and came into force on 26 June 2025. Flower may be sold only against a PT 33 (ภ.ท.33) prescription from an authorised practitioner. Each prescription covers no more than 30 days. Advertising flower and selling it online are prohibited.
Translator’s note: the original article adds further conditions on refills and on where the flower must come from. We could not confirm these in the text of the notification. Ask the prescriber or the Department of Thai Traditional and Alternative Medicine (DTAM) about the current rules. For how growing standards work, see Good Agricultural and Collection Practice (GACP), a quality standard for how medicinal plants are grown, harvested and recorded.
Translator’s note: whether nabiximols (Sativex) is registered as a medicine in Thailand is a separate question from whether a doctor may prescribe flower. The trial results above are for the registered spray, not for flower or home-made oil. Ask the treating neurologist whether the spray is available in Thailand. Ask the same about riluzole for ALS, and whether your health scheme covers it.
Translator’s note: in Thailand, ALS and Huntington’s disease are normally diagnosed and followed up in the neurology department of a university hospital or a large public hospital. If your local hospital has no neurologist, ask for a referral to a larger centre. Do not buy unlabelled oil or flower online. Online sale of flower is illegal. You also cannot know the THC and CBD dose, so you cannot compare your results with the trials.
Translator’s note: if a doctor prescribes a cannabis product, read the storage temperature on the label. Rooms in Thailand often reach 30–35 °C, which may be hotter than the label allows. See storing dried cannabis flower.
Huntington’s disease is also much less common in Asian populations. A pooled analysis of many studies (Pringsheim and colleagues, 2012) found a prevalence of 0.40 cases per 100,000 people in the three Asian studies. In Europe, North America and Australia the figure was 5.70 per 100,000, about 14 times higher.
Translator’s note: because the disease is rare here, many doctors see few cases. Families may need a referral to a larger centre. Because the disease is inherited, also ask whether relatives should see a genetic counsellor.
Share your experience: if you or a family member lives with motor neurone disease or Huntington’s disease in Thailand or Southeast Asia, post below this topic. Tell us whether spasticity was actively treated, and with what. The CANALS result is about spasticity specifically. For daily life, the question that matters most is whether this symptom gets attention at all, by any means.
This article is general educational information from the Asiannabis Community, not medical advice. Cannabis does not treat ALS or Huntington’s disease.
References
- Riva N et al. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS). The Lancet Neurology 2019;18(2):155–164.
- Blázquez C et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease. Brain 2011;134(Pt 1):119–136.
- Consroe P et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacology Biochemistry and Behavior 1991;40(3):701–708.
- Curtis A et al. A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Movement Disorders 2009;24(15):2254–2259.
- López-Sendón Moreno JL et al. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. Journal of Neurology 2016;263(7):1390–1400.
- Oikonomou P, Jost WH. Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review. Journal of Neural Transmission 2022;129(10):1247–1256.
- Pringsheim T et al. The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Movement Disorders 2012;27(9):1083–1091.